Cross-Induction of Anti-Complexing Protein Antibodies in Pa-tients Treated with Botulinum Toxin Formulations

Cross-Induction of Anti-Complexing Protein Antibodies in Patients Treated with Botulinum Toxin Formulations

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20250905005

Enrollment

137

Registered

2025-09-05

Start date

2021-06-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy human volunteers Enzyme-Linked Immunosorbent Assay, Botulinum Toxins, Immunoglobulins, Antibodies

Interventions

The blood will be drawn from the participant to examine the level of botulinum toxin antibody by using the ELISA technique.,Botulinum toxin injection for 50 units into the subjects. The blood will be

Active Comparator Other,Active Comparator Drug

Naive group,Treatment group

Eligibility

Sex/Gender

All

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Healthy male or female volunteers age 25-45 years, 2. No history of botulinum toxin treatment failure, 3. No history of immunodeficiency disease or taking any immunosuppressive drug,

Exclusion criteria

Exclusion criteria: 1. pregnant or lactating woman, 2. Was treated with botulinum toxin during 6 months prior, 3. Having the skin disease around the treated area

Design outcomes

Primary

Measure	Time frame
Percentage of anticomplexin protein Antibody 180 days after treatment Percentage of anticomplexin protein Antibody	—

Secondary

Measure	Time frame
None None None	—

Countries

Thailand

Contacts

Public ContactSurachet Sirisuthivoranunt

Research department

siri.surachet@gmail.com024199933

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026